FindTrial
Sign In

Extension Study from Confirmatory study in Pediatric Atopic Dermatitis Patients

Extension Study from Confirmatory study in Pediatric Atopic Dermatitis Patients

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220142
Enrollment
Unknown
Registered
2005-10-11
Start date
2005-10-11
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic Dermatitis

Interventions

investigational material(s) Generic name etc : Pimecrolimus INN of investigational material : Therapeutic category code : 269 Other agents for epidermis Dosage and Administration for Investigational

Sponsors

Novartis Pharma K.K.
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Inclusion Criteria - Patients who had completed the core study and whose participation in this study was considered appropriate as judged by the investigator - Patients whose guardians have given written informed consent to participation in this study Exclusion Criteria - Patients who failed in treatment compliance in the core study - Patients who had a major violation of the protocol in the core study

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Safety/Efficacy—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026